PTD-DBM vs Tripeptide-10 Citrulline
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: CXXC5-Dishevelled disrupting peptide, Protein Transduction Domain-Dishevelled Binding Motif
PTD-DBM is a synthetic peptide studied for hair regrowth. It pairs a cell-penetrating protein transduction domain with a Dishevelled-binding motif, letting it slip into cells and block CXXC5, a natural brake on the Wnt/beta-catenin pathway that hair follicles use to enter their growth phase. In mouse studies, releasing that brake (usually alongside topical valproic acid) restarted hair growth and even formed new follicles in wounded skin. The honest catch: the entire efficacy record is preclinical and comes mostly from one lab. There are no completed human trials, no regulatory approval, and no proof it works on people. For research use only.
Also: Decorinyl, Decorin-like tetrapeptide
Tripeptide-10 citrulline, sold as Decorinyl, is a small synthetic peptide (four residues, despite the name) designed by the Spanish ingredient maker Lipotec to mimic decorin, a protein that keeps collagen fibers neat and evenly sized. The pitch is better collagen, not more collagen. It is a cosmetic ingredient, not an FDA-approved drug, and almost all of the evidence comes from the company that makes it.
Key Comparison Insights
- Both peptides belong to the Skin & Hair category, suggesting similar primary applications.
- PTD-DBM has stronger research evidence (Animal Studies) compared to Tripeptide-10 Citrulline (Limited Research).
Detailed Comparison
| Attribute | PTD-DBM | Tripeptide-10 Citrulline |
|---|---|---|
| Category | Skin & Hair | Skin & Hair |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Hair follicles cycle into their growth (anagen) phase when Wnt/beta-catenin signaling switches on. CXXC5 is a negative feedback regulator of that pathway: it binds the intracellular protein Dishevelled (Dvl) and holds Wnt signaling down. PTD-DBM is a short Dvl-binding motif fused to a protein transduction domain (for cell entry) that competitively disrupts the CXXC5-Dvl interaction. With CXXC5 displaced, Dvl is free to activate Wnt/beta-catenin, which drives follicle stem-cell activation, anagen entry, and wound-induced hair neogenesis (new follicle formation in healing skin). It is typically studied together with valproic acid, a GSK-3beta inhibitor that pushes the same pathway from a different angle, so the two produce a synergistic effect greater than either alone. Be blunt: this mechanism is worked out in mice and cell models. The pathway is well characterized, but none of it has been validated in humans. | Decorin sits on collagen fibrils and controls how thick they grow and how tightly they pack. With age, decorin activity drops, and collagen fibers become uneven and disorganized, which is part of why older skin loses suppleness. Lipotec researchers took the two short sequences decorin uses to grab collagen, built a library of tetrapeptides around them, and screened them in a test-tube collagen assembly assay. The winner, tripeptide-10 citrulline, made fibrils thinner and more uniform in that assay. The idea is that a well-organized collagen network is more cohesive and supple. Whether a topical cream delivers enough peptide to the dermis to do this in real skin has not been independently shown. |
| Common Dosing | Supplied as 1 mg or 5 mg vials. A 5 mg vial in about 1 mL of water approximates the ~6 mg/mL used in the mouse study Once daily to the scalp in most community-reported routines | Around 0.01% peptide in a finished product Once or twice daily |
| Administration | Topical (applied to skin) in published research; usually co-applied with valproic acid | Topical (serums, creams) |
| Typical Duration | Applied over several weeks in animal studies | Studies ran 2 months (60 days); ongoing use for maintained effects |
| Best Time to Take | Not established (topical in animal studies) | Morning and/or evening skincare routine |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The core evidence comes from Lee SH and colleagues in the Choi laboratory at Yonsei University (South Korea), published in the Journal of Investigative Dermatology in 2017. In mice, topical PTD-DBM sped up the onset of anagen after shaving and promoted wound-induced hair neogenesis; a topical liquid of about 6 mg/mL PTD-DBM plus about 72 mg/mL valproic acid outperformed roughly 2% minoxidil in that model (the study reported these as solution concentrations: 2 mM, 500 mM, and 100 mM). The compound and its CXXC5-targeting mechanism are cited in more recent review articles on Wnt/beta-catenin hair therapies and short peptides for hair loss (2024-2025). What does not exist, as of 2026, is a single completed, peer-reviewed human efficacy trial. There is no FDA approval and no IND on record. Human dosing, safety, pharmacokinetics, and real-world efficacy are all unknown. The preclinical signal is genuinely interesting, but it is a long way from a proven treatment. | The founding paper is Puig, Garcia Anton and Mangues (Lipotec) in the Journal of Cosmetic Science, 2008, which describes the in vitro fibrillogenesis screen. Trade press reporting of the same company work described a 0.01 percent formula applied for two months that made collagen fibers more uniform in a handful of volunteers, and a placebo comparison (22 women on peptide, 21 on placebo) reporting a 54 percent rise in suppleness. Those numbers come from the manufacturer and are not easy to check against full published data. The one independent-looking human trial is Raikou and colleagues, Journal of Cosmetic Dermatology 2017: 24 volunteers split into four groups (combination with acetyl hexapeptide-3, each peptide alone, or neither) for 60 days, with some statistically significant differences in wrinkle microtopography and water loss. Six people per group is very small, and the authors themselves could not explain any synergy. Fair summary: a clever design with real in vitro logic, and thin human data. |
Frequently Asked Questions: PTD-DBM vs Tripeptide-10 Citrulline
What is the difference between PTD-DBM and Tripeptide-10 Citrulline?
PTD-DBM is a skin & hair peptide that ptd-dbm is a synthetic peptide studied for hair regrowth. it pairs a cell-penetrating protein transduction domain with a dishevelled-binding motif, letting it slip into cells and block cxxc5, a natural brake on the wnt/beta-catenin pathway that hair follicles use to enter their growth phase. in mouse studies, releasing that brake (usually alongside topical valproic acid) restarted hair growth and even formed new follicles in wounded skin. the honest catch: the entire efficacy record is preclinical and comes mostly from one lab. there are no completed human trials, no regulatory approval, and no proof it works on people. for research use only. Tripeptide-10 Citrulline is a skin & hair peptide that tripeptide-10 citrulline, sold as decorinyl, is a small synthetic peptide (four residues, despite the name) designed by the spanish ingredient maker lipotec to mimic decorin, a protein that keeps collagen fibers neat and evenly sized. the pitch is better collagen, not more collagen. it is a cosmetic ingredient, not an fda-approved drug, and almost all of the evidence comes from the company that makes it. The main differences lie in their mechanisms of action and clinical applications.
Which is better, PTD-DBM or Tripeptide-10 Citrulline?
Neither is universally "better" - the choice depends on your specific goals. PTD-DBM is typically used for skin & hair purposes, while Tripeptide-10 Citrulline is used for skin & hair. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can PTD-DBM and Tripeptide-10 Citrulline be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using PTD-DBM and Tripeptide-10 Citrulline together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.